Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials.

Kashiwagi A, Shestakova MV, Ito Y, Noguchi M, Wilpshaar W, Yoshida S, Wilding JPH.

Diabetes Ther. 2019 Oct 12. doi: 10.1007/s13300-019-00699-8. [Epub ahead of print]

PMID:
31606880
2.

Semaglutide in weight management - Author's reply.

Wilding JPH.

Lancet. 2019 Oct 5;394(10205):1226-1227. doi: 10.1016/S0140-6736(19)31904-X. No abstract available.

PMID:
31591978
3.

Correction to: Cardiac Autonomic Neuropathy in Obesity, Metabolic Syndrome and Prediabetes: A Narrative Review.

Williams SM, Eleftheriadou A, Alam U, Cuthbertson DJ, Wilding JPH.

Diabetes Ther. 2019 Oct 4. doi: 10.1007/s13300-019-00705-z. [Epub ahead of print]

PMID:
31583646
4.

Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review.

Williams SM, Eleftheriadou A, Alam U, Cuthbertson DJ, Wilding JPH.

Diabetes Ther. 2019 Sep 24. doi: 10.1007/s13300-019-00693-0. [Epub ahead of print] Review. Erratum in: Diabetes Ther. 2019 Oct 4;:.

PMID:
31552598
5.

Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.

Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Johansson PA, Langkilde AM, Raz I, Braunwald E, Sabatine MS.

Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31.

PMID:
31474116
6.

Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus.

Wilding JPH, Rigney U, Blak BT, Nolan ST, Fenici P, Medina J.

Diabetes Res Clin Pract. 2019 Sep;155:107791. doi: 10.1016/j.diabres.2019.107791. Epub 2019 Jul 17.

PMID:
31325543
7.

Should obesity be recognised as a disease?

Wilding JPH, Mooney V, Pile R.

BMJ. 2019 Jul 17;366:l4258. doi: 10.1136/bmj.l4258. No abstract available.

PMID:
31315832
8.

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I.

Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617. doi: 10.1016/S2213-8587(19)30180-9. Epub 2019 Jun 10. Erratum in: Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20.

PMID:
31196815
9.

A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors.

Brown E, Rajeev SP, Cuthbertson DJ, Wilding JPH.

Diabetes Obes Metab. 2019 Apr;21 Suppl 2:9-18. doi: 10.1111/dom.13650.

PMID:
31081592
10.

Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.

Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ.

Obes Rev. 2019 Jun;20(6):816-828. doi: 10.1111/obr.12841. Epub 2019 Apr 10. Review.

PMID:
30972878
11.

Incorporating patients' perspectives into the initial stages of core outcome set development: a rapid review of qualitative studies of type 2 diabetes.

Gorst SL, Young B, Williamson PR, Wilding JPH, Harman NL.

BMJ Open Diabetes Res Care. 2019 Feb 28;7(1):e000615. doi: 10.1136/bmjdrc-2018-000615. eCollection 2019. Review.

12.

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.

Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD.

Circulation. 2019 May 28;139(22):2516-2527. doi: 10.1161/CIRCULATIONAHA.119.039996. Epub 2019 Mar 18.

PMID:
30882239
13.

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.

Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD.

Circulation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18.

PMID:
30882238
14.

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.

Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.

PMID:
30786725
15.
16.

Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat.

Bowden Davies KA, Sprung VS, Norman JA, Thompson A, Mitchell KL, Harrold JOA, Finlayson G, Gibbons C, Wilding JPH, Kemp GJ, Hamer M, Cuthbertson DJ.

Med Sci Sports Exerc. 2019 Jun;51(6):1169-1177. doi: 10.1249/MSS.0000000000001901.

17.

Correction to: Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C.

Wong SPY, Huda M, English P, Bargiota A, Wilding JPH, Johnson A, Corrall R, Pinkney JH.

Diabetologia. 2019 Apr;62(4):732. doi: 10.1007/s00125-019-4818-0.

PMID:
30694351
18.

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.

Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.

PMID:
30424892
19.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators.

N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.

PMID:
30415602
20.

A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.

Shestakova MV, Wilding JPH, Wilpshaar W, Tretter R, Orlova VL, Verbovoy AF.

Diabetes Res Clin Pract. 2018 Dec;146:240-250. doi: 10.1016/j.diabres.2018.10.018. Epub 2018 Nov 1.

21.

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.

O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH.

Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16.

PMID:
30122305
22.

Patients' Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography.

Psarou A, Cooper H, Wilding JPH.

Diabetes Ther. 2018 Oct;9(5):1791-1810. doi: 10.1007/s13300-018-0490-5. Epub 2018 Aug 17. Review.

23.

Vitamin D receptor ligands attenuate the inflammatory profile of IL-1β-stimulated human white preadipocytes via modulating the NF-κB and unfolded protein response pathways.

Zhu J, Bing C, Wilding JPH.

Biochem Biophys Res Commun. 2018 Sep 5;503(2):1049-1056. doi: 10.1016/j.bbrc.2018.06.115. Epub 2018 Jun 23.

PMID:
29935184
24.

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS.

Am Heart J. 2018 Jun;200:83-89. doi: 10.1016/j.ahj.2018.01.012. Epub 2018 Feb 7.

PMID:
29898853
25.

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.

Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, Fu AZ, Bodegård J, Blak BT, Wittbrodt E, Thuresson M, Fenici P, Hammar N, Kosiborod M; CVD-REAL Investigators and Study Group.

J Am Coll Cardiol. 2018 Jun 5;71(22):2497-2506. doi: 10.1016/j.jacc.2018.01.085.

26.

Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.

Thuresson M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Wittbrodt E, Hammar N, Fenici P, Kosiborod M; CVD-REAL Investigators and Study Group.

Diabetes Care. 2018 Jun;41(6):e106-e108. doi: 10.2337/dc18-0338. No abstract available.

PMID:
29784708
27.

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials.

Ahrén B, Atkin SL, Charpentier G, Warren ML, Wilding JPH, Birch S, Holst AG, Leiter LA.

Diabetes Obes Metab. 2018 Sep;20(9):2210-2219. doi: 10.1111/dom.13353. Epub 2018 Jun 12.

28.

Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.

Wilding JPH.

Clin Obes. 2018 Jun;8(3):211-225. doi: 10.1111/cob.12248. Epub 2018 Apr 24.

29.

Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes.

Bowden Davies KA, Sprung VS, Norman JA, Thompson A, Mitchell KL, Halford JCG, Harrold JA, Wilding JPH, Kemp GJ, Cuthbertson DJ.

Diabetologia. 2018 Jun;61(6):1282-1294. doi: 10.1007/s00125-018-4603-5. Epub 2018 Apr 18.

PMID:
29671031
30.

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.

Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Jørgensen ME, Wittbrodt ET, Thuresson M, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group.

Diabetes Obes Metab. 2018 Aug;20(8):1983-1987. doi: 10.1111/dom.13299. Epub 2018 Apr 17.

31.

Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group.

Circulation. 2018 Feb 27;137(9):989-991. doi: 10.1161/CIRCULATIONAHA.117.031847. No abstract available.

PMID:
29483180
32.

Why I eat at night: A qualitative exploration of the development, maintenance and consequences of Night Eating Syndrome.

Shillito JA, Lea J, Tierney S, Cleator J, Tai S, Wilding JPH.

Appetite. 2018 Jun 1;125:270-277. doi: 10.1016/j.appet.2018.02.005. Epub 2018 Feb 14.

PMID:
29454015
33.

Newer GLP-1 receptor agonists and obesity-diabetes.

Brown E, Cuthbertson DJ, Wilding JP.

Peptides. 2018 Feb;100:61-67. doi: 10.1016/j.peptides.2017.12.009. Review.

PMID:
29412833
34.

DECLARE-TIMI 58: Participants' baseline characteristics.

Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Johansson PA, Sabatine MS, Wiviott SD.

Diabetes Obes Metab. 2018 May;20(5):1102-1110. doi: 10.1111/dom.13217. Epub 2018 Feb 14.

PMID:
29322605
35.

Combination therapy for obesity.

Wilding JP.

J Psychopharmacol. 2017 Nov;31(11):1503-1508. doi: 10.1177/0269881117737401. Epub 2017 Nov 13. Review.

PMID:
29132230
36.

Evaluation of Aintree LOSS, a community-based, multidisciplinary weight management service: outcomes and predictors of engagement.

Steele T, Narayanan RP, James M, James J, Mazey N, Wilding JPH.

Clin Obes. 2017 Dec;7(6):368-376. doi: 10.1111/cob.12216. Epub 2017 Sep 4.

PMID:
28871633
37.

Arrhythmogenic gene remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction.

Ashrafi R, Modi P, Oo AY, Pullan DM, Jian K, Zhang H, Gerges JY, Hart G, Boyett MR, Davis GK, Wilding JPH.

Exp Physiol. 2017 Nov 1;102(11):1424-1434. doi: 10.1113/EP086412. Epub 2017 Sep 24.

38.

Screening methods for obstructive sleep apnoea in severely obese pregnant women.

Longworth H, McCallin K, Narayanan RP, Turner MA, Quenby S, Rycroft D, Charnley M, Abayomi J, Topping J, Weeks AD, Wilding JPH.

Clin Obes. 2017 Aug;7(4):239-244. doi: 10.1111/cob.12196. Epub 2017 May 29.

PMID:
28557355
39.

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*.

Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18.

40.

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.

Budoff MJ, Wilding JPH.

Int J Clin Pract. 2017 May;71(5). doi: 10.1111/ijcp.12948. Review.

41.

Medication use for the treatment of diabetes in obese individuals.

Wilding JPH.

Diabetologia. 2018 Feb;61(2):265-272. doi: 10.1007/s00125-017-4288-1. Epub 2017 May 14. Review.

42.

Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation.

Bray GA, Kim KK, Wilding JPH; World Obesity Federation.

Obes Rev. 2017 Jul;18(7):715-723. doi: 10.1111/obr.12551. Epub 2017 May 10. Review.

PMID:
28489290
43.

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.

O'Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, Brett J, Cancino AP, Wilding JPH; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups.

Diabetes Obes Metab. 2017 Nov;19(11):1529-1536. doi: 10.1111/dom.12963. Epub 2017 Jul 21.

44.

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.

le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group.

Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23. Erratum in: Lancet. 2017 Apr 8;389(10077):1398.

PMID:
28237263
45.

Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.

Rajeev SP, Sprung VS, Roberts C, Harrold JA, Halford JC, Stancak A, Boyland EJ, Kemp GJ, Cuthbertson DJ, Wilding JP.

BMJ Open. 2017 Jan 27;7(1):e013539. doi: 10.1136/bmjopen-2016-013539.

46.

What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?

Cuthbertson DJ, Steele T, Wilding JP, Halford JC, Harrold JA, Hamer M, Karpe F.

Int J Obes (Lond). 2017 Jun;41(6):853-865. doi: 10.1038/ijo.2017.4. Epub 2017 Jan 12. Review.

PMID:
28077863
47.

Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response.

Thondam SK, Daousi C, Wilding JP, Holst JJ, Ameen GI, Yang C, Whitmore C, Mora S, Cuthbertson DJ.

Am J Physiol Endocrinol Metab. 2017 Mar 1;312(3):E224-E233. doi: 10.1152/ajpendo.00347.2016. Epub 2017 Jan 10.

48.

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.

Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE.

Diabetes. 2017 Feb;66(2):241-255. doi: 10.2337/db16-0806. Epub 2016 Dec 15. Review.

49.

Research update for articles published in EJCI in 2014.

Agra RM, Al-Daghri NM, Badimon L, Bodi V, Carbone F, Chen M, Cubedo J, Dullaart RP, Eiras S, García-Monzón C, Gary T, Gnoni A, González-Rodríguez Á, Gremmel T, Hafner F, Hakala T, Huang B, Ickmans K, Irace C, Kholová I, Kimer N, Kytö V, März W, Miazgowski T, Møller S, Montecucco F, Niccoli G, Nijs J, Ozben S, Ozben T, Papassotiriou I, Papastamataki M, Reina-Couto M, Rios-Navarro C, Ritsch A, Sabico S, Seetho IW, Severino A, Sipilä J, Sousa T, Taszarek A, Taurino F, Tietge UJ, Tripolino C, Verloop W, Voskuil M, Wilding JP.

Eur J Clin Invest. 2016 Oct;46(10):880-94. doi: 10.1111/eci.12671. No abstract available.

PMID:
27571922
50.

Weighing up dietary patterns - Authors' reply.

Bray GA, Frühbeck G, Ryan DH, Wilding JP.

Lancet. 2016 Aug 20;388(10046):759-60. doi: 10.1016/S0140-6736(16)31359-9. No abstract available.

PMID:
27560275

Supplemental Content

Loading ...
Support Center